Identifying responders to trastuzumab therapy in breast cancer. - Wikidata - awgldk - TriplyDB

Identifying responders to trastuzumab therapy in breast cancer.

Identifying responders to trastuzumab therapy in breast cancer.

http://www.wikidata.org/entity/Q37889967

about

Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment.

P2860

Q37686308-F08C8C28-394F-4465-A542-7B6E1145B7F0 Q46431111-DF4A7B5D-FA53-45AA-BFAE-667154A942D9

P2860

Identifying responders to trastuzumab therapy in breast cancer.

http://www.wikidata.org/entity/Q37889967

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Identifying responders to trastuzumab therapy in breast cancer.

@en

Identifying responders to trastuzumab therapy in breast cancer.

@nl

type

label

Identifying responders to trastuzumab therapy in breast cancer.

@en

Identifying responders to trastuzumab therapy in breast cancer.

@nl

prefLabel

Identifying responders to trastuzumab therapy in breast cancer.

@en

Identifying responders to trastuzumab therapy in breast cancer.

@nl

P1433

Q37889967-6E620B3C-3E9B-4DAC-AED4-AB1CDF6DB2D0

P1476

Q37889967-3A544D83-A6E3-4244-9317-AD5BB3FE6E10

P2093

Q37889967-4BC4C5DF-7147-4E38-AEC1-89FCA062FBFB

Q37889967-FCEAF21B-FBAA-48FC-901A-D11195BA77A1

P2860

Q37889967-0057F67F-4366-4454-A314-DD55B91E63B5

Q37889967-01CFEF2C-D42C-4845-A0CF-36431E4A3783

Q37889967-16921081-336D-4A57-A231-199B6AB9680C

Q37889967-1E85062E-356D-494B-B65F-57BD50656DFF

Q37889967-25B54E5D-60CB-43A4-9C75-B5574CA1934F

Q37889967-25BF92E7-045B-4CEF-9187-5CAA8B731987

Q37889967-28321DA9-A422-47F3-AA8F-A6E047C70763

Q37889967-348B894A-04E5-4C4F-B2C5-C4D0C9EEAB94

Q37889967-3DC2E2C7-EA5A-49B3-B3B1-B61DB0219D24

Q37889967-4F72FED1-D873-4853-BF1E-940CA16C826D

P304

Q37889967-6F81EA12-DB50-481B-9540-FD478DB75504

P31

Q37889967-CCFC0531-CC8A-4E64-A65B-1F20BDF60649

P356

Q37889967-05D629BE-FCB9-4102-8CA3-C053E31B9F5C

P407

Q37889967-8C389A5B-C049-405B-B7DB-DC0E160DC1F2

P433

Q37889967-F70A4E90-F834-4C90-B115-BB4F9EDD2386

P478

Q37889967-A1340C1C-AF79-4C33-A48D-65AD30911E13

P577

Q37889967-2B023FFD-1585-4C28-97D2-864CAF5BACF5

P5875

Q37889967-EA23C171-B85D-467E-91EE-989E233371A9

P698

Q37889967-DFC34605-2036-4329-A484-C1D851575046

P356

P1433

Future Oncology

P1476

Identifying responders to trastuzumab therapy in breast cancer.

@en

P2093

Anja Brügmann

http://www.w3.org/2001/XMLSchema#string

Boe S Sorensen

http://www.w3.org/2001/XMLSchema#string

P2860

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab

Isolation of rare circulating tumour cells in cancer patients by microchip technology

Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling

Structure of HER receptors and intracellular localisation of downstream effector elements gives insight into mechanism of tumour growth promotion

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

767-773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.11.44

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51221625

http://www.w3.org/2001/XMLSchema#string

P698

21675839

http://www.w3.org/2001/XMLSchema#string